TAM March/April 2026 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
March/April 2026, Volume 34, Issue 2
Overview
- CME Credit Available: 12.25 AMA PRA Category 1 Credits™
- Release Date: April 30, 2026
- Expiration Date: April 30, 2027
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
Learning Objectives
On completion of this activity, which contains 9 articles on important new data presented at the 2026 Conference on Retroviruses and Opportunistic Infections, the learner will be better able to:
- Describe basic science research on HIV, including viral reservoirs and cure
- List neurologic HIV complications, including coinfections and comorbidities
- Describe the latest research on antiretroviral therapy for adult, maternal, and pediatric populations with HIV
- Describe the latest innovations in HIV care and service delivery
- List the current diagnostic and treatment options for tuberculosis and other opportunistic infections in adults and children with HIV
- Describe the recent advances in the epidemiology and treatment of viral hepatitis
- Describe important data on HIV comorbidities
- List the clinical manifestations and treatment options for acute and postacute COVID-19
- Describe the epidemiologic trends and the latest preventative methods for HIV and other sexually transmitted infections
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.
Intended Audience
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections. This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
CME Information
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from April 30, 2026, to April 30, 2026. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities.
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA has identified and mitigated ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below.
Contributors
Dr Antar reported no relevant financial relationships with ineligible companies. (Updated April 8, 2026)
Dr Brown reported serving as a consultant for EMD-Serono, Janssen, Merck & Co, Inc, Gilead Sciences, and ViiV Healthcare. (Updated March 30, 2026)
Dr Buchbinder reported grant support awarded to her institution from Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare; receiving noncash provision of medicines, equipment, or administrative cash support from Gilead Sciences, Inc, and ViiV Healthcare; and serving as an advisor to Merck & Co, Inc. (Updated March 18, 2026)
Dr Chan reported no relevant financial relationships with ineligible companies. (Updated March 26, 2026)
Dr Corley reported no relevant financial relationships with ineligible companies. (Updated March 26, 2026)
Dr Gunaratne reported no relevant financial relationships with ineligible companies. (Updated March 26, 2026)
Dr Havlir reported nonfinancial support from ViiV Healthcare. (Updated April 2, 2026)
Dr Joseph reported no relevant financial relationships with ineligible companies. (Updated March 26, 2026)
Dr Kerkhoff reported no relevant financial relationships with ineligible companies. (Updated March 28, 2026)
Dr Liu reported grant support awarded to his institution from Gilead Sciences, Inc., Merck, and ViiV Healthcare; noncash provision of medicines, equipment, or administrative support from Gilead Sciences, Inc., and ViiV Healthcare; and serving as a consultant to Gilead Sciences, Inc. (Updated March 23, 2026)
Dr Sarkar reported no relevant financial affiliations with ineligible companies. (Updated March 30, 2026)
Dr Stevenson reported no relevant financial relationships with ineligible companies. (Updated March 17, 2026)
Dr Taylor reported serving as an advisor or consultant to Gilead Sciences, Inc. (Updated April 15, 2026)
Dr Tieu reported grant support awarded to her institution from Gilead Sciences, Inc. (Updated March 26, 2026)
Dr Wilkin reported serving as a consultant to GlaxoSmithKline/ViiV Healthcare and Merck and Co., Inc.; grant support awarded to his institution from GlaxoSmithKline/ViiV Healthcare and Merck and Co., Inc. (Updated March 26, 2026)
Dr Zucker reported no relevant financial relationships with ineligible companies. (Updated March 28, 2026)
Planners/Reviewers
Planner/Reviewer 1 reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated April 10, 2026)
Reviewer 2 reported no relevant financial relationships with ineligible companies. (Update April 29, 2026)
Planner/Reviewer 3 reported no relevant financial relationships with ineligible companies. (Updated April 29, 2026)
Topics in Antiviral Medicine Editorial Board
Dr Richman reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated April 10, 2026)
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Platinum Supporters
Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare
Additional Supporter
Hologic, Inc
Contact Information
If you have any questions about this activity, please contact the IAS–USA:
Email: journal@iasusa.org
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.
You must be logged in to access this course.